Guggenheim Raises argenex (NASDAQ:ARGX) Price Target to $1,185.00

argenex (NASDAQ:ARGX) had its price objective upped by research analysts at Guggenheim from $1,135.00 to $1,185.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 28.79% from the stock’s previous close.

Several other equities research analysts have also commented on ARGX. Oppenheimer cut their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating for the company in a report on Thursday, April 2nd. Citizens Jmp dropped their target price on shares of argenex from $944.00 to $932.00 and set a “market outperform” rating on the stock in a research report on Friday. Glj Research raised shares of argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Morgan Stanley upped their price target on shares of argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research note on Thursday, June 11th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,044.78.

argenex Trading Down 0.5%

NASDAQ ARGX opened at $920.11 on Friday. The stock has a market capitalization of $57.56 billion, a price-to-earnings ratio of 41.14, a PEG ratio of 1.05 and a beta of 0.45. argenex has a twelve month low of $587.37 and a twelve month high of $953.58. The stock has a 50-day moving average of $865.90 and a 200 day moving average of $814.39.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 44.37% and a net margin of 31.31%. Equities analysts predict that argenex will post 26.27 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

Hedge funds have recently modified their holdings of the stock. Merit Financial Group LLC grew its position in argenex by 17.1% in the second quarter. Merit Financial Group LLC now owns 466 shares of the company’s stock valued at $432,000 after acquiring an additional 68 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of argenex by 9.6% in the second quarter. Farther Finance Advisors LLC now owns 365 shares of the company’s stock valued at $338,000 after purchasing an additional 32 shares during the period. Ballentine Partners LLC grew its holdings in argenex by 30.8% during the 2nd quarter. Ballentine Partners LLC now owns 772 shares of the company’s stock valued at $716,000 after purchasing an additional 182 shares in the last quarter. Peregrine Capital Management LLC acquired a new stake in argenex during the 2nd quarter valued at $27,584,000. Finally, Sequoia Financial Advisors LLC increased its stake in argenex by 4.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,045 shares of the company’s stock worth $1,897,000 after buying an additional 84 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported Q2 EPS of $7.32, topping estimates, with revenue of $1.54 billion, also above expectations, reinforcing the company’s strong execution. Argenx reports quarterly earnings data
• Positive Sentiment: Vyvgart sales jumped sharply in the second quarter, with multiple reports highlighting roughly 60% growth, supporting confidence in argenx’s core autoimmune franchise. Reuters article on Vyvgart sales jump
• Positive Sentiment: Analysts remained constructive, with Guggenheim initiating/maintaining a Buy view and Citizens JMP still rating the shares Market Outperform despite a small target cut to $932. Guggenheim Buy rating article Citizens JMP price target cut article
• Positive Sentiment: Recent coverage emphasized surging profitability, strong cash generation, and pipeline catalysts, which may be lifting long-term growth expectations for ARGX. Seeking Alpha rating upgrade article
• Neutral Sentiment: argenx also held an earnings call and issued a half-year 2026 business update, but these items mainly reinforce the already reported results rather than adding new surprises. Business update
• Negative Sentiment: Citizens JMP lowered its price target from $944 to $932, signaling slightly less upside even though the firm kept a positive rating. Price target lowered

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.